Also, we found that high phosphorylation of EGFR/MET could maintain the hyperphosphorylation status of some RTKs which were clinical targets for HCC treatment, such as PDGFRβ and FGFR1, and it was obvious in HCC cell lines with MET amplification. The gene discussed is EGFR; the disease is hepatocellular carcinoma.